- Home
- AARD vs WIA Comparison
AARD vs WIA Comparison
Compare AARD & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- WIA
- Stock Information
- Founded
- AARD 2017
- WIA 2003
- Country
- AARD United States
- WIA United States
- Employees
- AARD N/A
- WIA N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- WIA Trusts Except Educational Religious and Charitable
- Sector
- AARD Health Care
- WIA Finance
- Exchange
- AARD Nasdaq
- WIA Nasdaq
- Market Cap
- AARD 231.9M
- WIA 197.8M
- IPO Year
- AARD 2025
- WIA N/A
- Fundamental
- Price
- AARD $9.91
- WIA $8.45
- Analyst Decision
- AARD Strong Buy
- WIA
- Analyst Count
- AARD 8
- WIA 0
- Target Price
- AARD $30.63
- WIA N/A
- AVG Volume (30 Days)
- AARD 162.6K
- WIA 39.2K
- Earning Date
- AARD 11-13-2025
- WIA 01-01-0001
- Dividend Yield
- AARD N/A
- WIA 12.29%
- EPS Growth
- AARD N/A
- WIA N/A
- EPS
- AARD N/A
- WIA N/A
- Revenue
- AARD N/A
- WIA N/A
- Revenue This Year
- AARD N/A
- WIA N/A
- Revenue Next Year
- AARD N/A
- WIA N/A
- P/E Ratio
- AARD N/A
- WIA N/A
- Revenue Growth
- AARD N/A
- WIA N/A
- 52 Week Low
- AARD $4.88
- WIA $7.56
- 52 Week High
- AARD $19.58
- WIA $8.91
- Technical
- Relative Strength Index (RSI)
- AARD 39.27
- WIA 44.49
- Support Level
- AARD $9.34
- WIA $8.35
- Resistance Level
- AARD $11.51
- WIA $8.54
- Average True Range (ATR)
- AARD 0.85
- WIA 0.07
- MACD
- AARD -0.01
- WIA -0.00
- Stochastic Oscillator
- AARD 20.39
- WIA 19.05
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.